Controls how your cells take up glucose - insulin binding here triggers GLUT4 translocation, glycogen synthesis, and mTOR activation across muscle, fat, and liver. Insulin and its analogs are the largest single category of approved peptide drugs by patient volume. Structural biology is mature enough to engineer analogs with altered duration, selectivity, and signaling bias - making INSR the most commercially developed peptide target in medicine.
INSR is the receptor tyrosine kinase that converts circulating insulin into whole-body glucose homeostasis - the central node for type 2 diabetes, insulin resistance, and metabolic syndrome pathophysiology. Insulin and its analogs constitute the largest single category of approved peptide drugs by patient volume. The insulin receptor's structural biology now provides atomic-resolution templates for engineering analogs with altered duration, selectivity, and signaling bias, making INSR the most commercially and pharmacologically mature peptide target in medicine.
INSR (chromosome 19p13.2, 1382 aa precursor cleaved to α and β subunits) forms a disulfide-linked (αβ)₂ heterotetrameric receptor: two extracellular α-subunits (~135 kDa each) carry the L1-CR-L2 ligand-binding domains, and two β-subunits (~95 kDa each) carry the transmembrane helix and intracellular kinase domain. Insulin engages the receptor asymmetrically - Site 1 (B-chain residues B24–B26 and A21) contacts L1 of one α-subunit and the αCT helix of the opposite α-subunit; Site 2 engages a second lower-affinity site. This cross-linking drives the allosteric conformational change that releases the activation loop from autoinhibited position → trans-autophosphorylation of Tyr1158/Tyr1162/Tyr1163 → full kinase activation. Primary downstream: IRS-1/2 → PI3K → Akt → AS160/GLUT4 translocation (glucose uptake), glycogen synthesis (GSK-3β inhibition), lipid synthesis (SREBP1), and protein synthesis (mTORC1). Parallel: Shc → Ras/MAPK/ERK (mitogenic). Two IR isoforms exist: IR-A (exon 11 excluded, fetal/cancer, high IGF-2 affinity) and IR-B (exon 11 included, metabolic tissues). Type 2 diabetes involves post-receptor IRS-1 serine phosphorylation → insulin resistance; type 1 involves autoimmune β-cell destruction requiring exogenous insulin replacement.
Approved insulin analogs include: regular human insulin (rapid-acting), NPH (intermediate), insulin lispro/aspart/glulisine (rapid-acting analogs with B-chain substitutions that reduce self-association), insulin glargine/detemir/degludec (long-acting via isoelectric precipitation or fatty acid albumin binding). Inhaled insulin (Afrezza) is approved for prandial use. For peptide research, the tractable recipes are: insulin mini-analogs (single-chain insulins with A-B linkers for oral bioavailability) that maintain Site 1 engagement; B-chain C-terminus truncations and cyclic constrained variants for ultrafast-acting formulations; INSR/IGF-1R selectivity scans using Site 2 modifications to separate metabolic from mitogenic signaling; and glucose-responsive insulin conjugates where a glucose-sensing moiety (phenylboronic acid or concanavalin A) gates receptor-binding conformational switching for closed-loop peptide therapeutics.
EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ · 31 aa · @peptidemodel
| # | id | title | author | status | refs | ipSAE_d0chn | ♥ |
|---|---|---|---|---|---|---|---|
| 1 | pep-10787 | C-peptide: the insulin co-release signal tied to diabetes nerve & vessel health | pe@peptidemodel | 8 | — | 0 | |
| 2 | pep-04453 | Insulin B chain: half of the blood-sugar hormone insulin | pe@peptidemodel | 3 | — | 0 | |
| 3 | pep-04454 | Insulin A chain: the smaller half of the blood-sugar hormone | pe@peptidemodel | 3 | — | 0 |
No discussion threads yet.